Gynecologic Cancers
Off-the-Shelf Cervical Cancer Vaccine Shows Promising Initial Results in HPV16+ Patients
May 13, 2022
Article
Atezolizumab in conjunction with VB10.16, the first off-the-shelf therapeutic cancer vaccine, elicited encouraging responses in pretreated patients with HPV16-positive advanced cervical cancer.
Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer
April 18, 2022
Article
New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.
Bringing a New Approach to Symptom Management in Ovarian Cancer
April 15, 2022
Podcast
In this episode of “The Vitals,” Heidi Donovan, PhD, RN, discusses novel symptom management intervention for women with recurrent ovarian cancer.
Investigators Inch Closer to Unlocking CAR T-Cell Therapy Potential in Solid Tumors
April 13, 2022
Article
Findings from a phase 1 trial evaluating CAR T-cell therapy in patients with solid tumors showed promising clinical benefit with the treatment strategy.
Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer
April 10, 2022
Video
Courtney Arn, APRN-CNP, a nurse practitioner comments on the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Rucaparib Improves PFS in Advanced Ovarian Cancer
April 08, 2022
Article
The PARP inhibitor rucaparib significantly prolonged progression-free survival compared with placebo as a first-line maintenance treatment in previously treated patients with ovarian cancer.
FDA Follow-Up: Utilizing Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
April 08, 2022
Article
Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Niraparib/Bevacizumab Combo Elicits Promising Responses in Advanced Ovarian Cancer, Regardless of Biomarker Status
March 31, 2022
Article
The PARP inhibitor, niraparib, in conjunction with the VEGF inhibitor, bevacizumab, resulted in encouraging responses from patients with advanced ovarian cancer.
Patient-Reported Outcomes Demonstrate Satisfaction With Pembrolizumab in Advanced Cervical Cancer
March 27, 2022
Article
Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.
Adding Atezolizumab to Chemoradiation Promotes T-Cell Clonal Expansion in Node-Positive Cervical Cancer
March 26, 2022
Article
Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.